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Purpose: To identify non-housekeeping genes definitively expressed in the human trabecular meshwork (TM).
Methods: Microarray gene expression data on TM cultured cells from four studies were compared. Genes that were
queried in at least three studies and assessed to be expressed in at least three studies were considered definitively expressed
genes of the human TM. Housekeeping genes were removed from this set of genes. The non-housekeeping TM gene
profile was analyzed for pathway enrichment and microRNA targeting, using bioinformatics tools. The results were
compared with results of previous non-array based studies.
Results: Nine hundred and sixty-two genes were identified as non-housekeeping TM expressed genes. Analysis of these
by Kyoto Encyclopedia of Genes and Genomes led to identification of two enriched biologic pathways that achieved a
highly significant Bonferroni p-value (p≤0.01): focal adhesion and extracellular matrix (ECM)-receptor interaction. Many
of the genes were previously implicated in TM-related functions and the TM-associated disease glaucoma; however, some
are novel. MicroRNAs known to be expressed in the trabecular meshwork were predicted to target some of the genes. Ten
genes identified here, ALDH1A1 (aldehyde dehydrogenase 1 family, member A1), CDH11 (cadherin 11, type 2, OB-
cadherin), CXCR7 (chemokine (C-X-C motif) receptor 7), CHI3L1 (chitinase 3-like 1), FGF2 (fibroblast growth factor
2), GNG11 (guanine nucleotide binding protein [G protein], gamma 11), IGFBP5 (insulin-like growth factor binding
protein 5), PTPRM (protein tyrosine phosphatase, receptor type, M), RGS5 (regulator of G-protein signaling 5), and
TUSC3 (tumor suppressor candidate 3), were also reported as TM expressed genes in three earlier non-microarray based
studies.
Conclusions: A transcriptome consisting of 962 non-housekeeping genes definitively expressed in the human TM was
identified. Multiple genes and microRNAs are proposed for further study for a better understanding of TM physiology.
The trabecular meshwork (TM) is located at the angle
formed by the cornea and iris. The tissue is a major component
of the conventional outflow pathway of aqueous humor and,
thus, significantly modulates outflow of this fluid from the
anterior chamber to venous blood via Schlemm’s canal [1].
Decreased outflow resulting from increased TM resistance
causes increased intraocular pressure (IOP), which is a major
risk factor for primary open angle glaucoma (POAG) [2-4].
The TM and aqueous humor also have roles in physiologic
processes involving detoxification reactions and the immune
system [5]. The precise mechanisms by which the TM affects
these processes and regulates intraocular pressure are largely
unknown.  Analysis  of  the  transcriptome  of  the  TM  and
changes in the transcriptome due to conditions relevant to
glaucoma may help illuminate these mechanisms. To this end,
several studies have been performed within the past decade.
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Initially,  human  TM  expressed  genes  were  assessed  by
sequencing some clones of TM cDNA libraries [6,7]. Since
the  introduction  of  high-density  chips  for  assessing  gene
expression  profiles,  four  genome-wide  TM  transcriptome
analyses that addressed glaucoma-relevant parameters and
that included data on untreated TM cells have been published
[8-11].  In  one  of  the  studies,  gene  expression  profiles  of
cultured  and  native  TM  cells  were  compared,  and  it  was
reported that there was more than 90% similarity between
expressed  genes  [10].  The  remaining  three  studies  used
cultured TM cells. The data on the control cultures that were
untreated in each of the four global studies allow assessment
of the TM transcriptome. However, the profiles for the control
cultures in these studies were not the same. The variations are
due  to  a  combination  of  factors,  including  individual
variations, the complement of genes queried on the different
chips  used,  and  technical  parameters  of  the  hybridization
reactions and analyses protocols. Here, we report results of a
meta-analysis based on the four studies, with the objective of
defining a TM transcriptome that is most likely to include only
true positive non-housekeeping genes expressed in primary
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241TM cultures of various sources. Housekeeping genes were
designated by two recent studies on gene expression profiles
of multiple human tissues using microarray and RNA deep
sequencing data [12,13]. The derived non-housekeeping TM
gene expression profile was analyzed using bioinformatics
tools.  The  results  were  compared  with  those  of  previous
studies on gene expression in normal human TM, including
results of a recent study based on serial analysis of gene
expression (SAGE) [6,7,14].
METHODS
Microarray gene expression data on control TM cultured cells
from four studies were downloaded [8-11] (Gene Expression
Omnibus      [GEO]       accession        numbers       GSE492,     
GSE4316,     GSE7144,  and    GSE27275).   Features  of 
the microarray studies, including source of TM RNAs, chips
used, and number of genes queried on the chips, are presented
in Table 1. For the three studies in which Affymetrix chips
were used, a hybridization threshold signal of 200 was used
for expressed genes [8-10]. The same cutoff value was applied
in the microarray study used here to define housekeeping
genes; the cutoff was based on results of hybridizations to
negative control probes placed on these chips and derived with
the objective of achieving an optimal false positive to false
negative ratio [12]. Others have also used the same cutoff
[15].  Earlier  studies  based  on  instrument  parameters  and
statistical analysis have recommended that signals lower than
200 on Affymetrix chips should not be considered in gene
expression  studies  [16,17].  For  the  Illumina  chips,  a
hybridization cutoff signal was chosen so that approximately
the same fraction (50%) of genes queried on Affymetrix and
Illumina chips would be considered genes expressed in the
human TM. Hybridization signal of 200 was surpassed for
almost all genes queried on the Illumina chips. Genes were
grouped based on the number of studies in which they were
queried. Subsequently, expressed genes were assessed with
consideration of the number of studies in which hybridization
thresholds were met and the number of studies in which they
were queried. Only genes that were queried in at least three
studies, and whose hybridization signals met the threshold in
at least three studies, were considered definitively expressed
genes of the human TM. Housekeeping (HK) genes were
removed from this set of genes. Results of two recent studies
that aimed to identify ubiquitously expressed genes in human
cells were used to define housekeeping genes. One study,
based on publically available microarray gene expression data
on 18 human tissues, identified 2,403 genes expressed in at
least 16 of those tissues [12]. The second study was more
recent, and it was based on RNA deep sequencing data derived
from diverse tissues and cell culture samples; it identified
7,897 ubiquitously expressed genes. Genes included in one or
both of these studies (8,416 genes) were removed from the
aforementioned list of definitively expressed genes of the
human TM to derive a list of definitively expressed non-
housekeeping genes of the human TM (non-HK TM genes).
This set of genes was used in subsequent in silico analyses.
Enriched functional pathways and functional categories or
gene ontology terms annotated by Kyoto Encyclopedia of
Genes  and  Genomes  (KEGG)  [18]  and  GO  [19]  were
identified using The Database for Annotation, Visualization
and Integrated Discovery (DAVID) bioinformatics resource
[20].  A  cutoff  Bonferroni-p  value  of  0.01  was  used  for
enriched KEGG pathways or GO functions. Non-HK TM
genes whose expressions were altered by glaucoma-relevant
experimental  manipulations  were  identified.  MicroRNAs
whose target genes were enriched in the non-HK TM genes
were also identified, using BioProfiling. Finally, non-HK TM
genes identified here were compared to TM transcriptomes
assessed by non-microarray protocols. The significance of the
findings is discussed.
RESULTS
Approximately 50% of the genes queried on the chips of each
study were expressed in the human TM (Table 1). A total of
21,813 genes were queried; the number of genes queried one,
two, three, or four times are shown in Figure 1, and the genes
TABLE 1. FEATURES OF MICROARRAY STUDIES USED TO ASSESS GENE EXPRESSION IN HUMAN TRABECULAR MESHWORK.
Reference of
study
Source of data Microarray chip No. genes
queried*
No. genes
expressed
(%)**
[8] Pooled RNA of 5 pairs of eyes; average of duplicate
chips
Affymetrix Genome U95Av2Human 8963 4419 (49.3%)
[9] Pooled RNA of 5 pairs of eyes; average of duplicate
chips
Affymetrix Human Genome U133A 12962 7117 (54.9%)
[10] RNA of 3 pairs of eyes; one chip per individual;
average of 3 chips
Affymetrix Human Genome U133 plus
2.0
20203 10356 (51.2%)
[11] RNA of 2 pairs of eyes; two chips per individual;
average of 4 chips
Illumina HumanRf-8 V2 17133 8566 (50.0%)
        * http://www.affymetrix.com/support/technical/libraryfilesmain.affx  and  http://www.illumina.com/support/
        annotation_files.ilmn. ** As per criteria described in text.
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242are listed in Appendix 1. Of these, 5,379 genes met expression
threshold  criteria  in  at  least  three  studies,  and  they  are
considered definitively expressed genes of the human TM.
The majority of these (4,417 genes; 82%) were housekeeping
genes;  962  (18%)  were  non-HK  TM  expressed  genes
(Appendix 1). Analysis of the 962 genes by KEGG led to
identification of two enriched biologic pathways that achieved
a  highly  significant  Bonferroni  p-value  (p≤0.01):  focal
adhesion  (Bonferroni  p=0.00275)  and  extracellular  matrix
(ECM)-receptor interaction (Bonferroni p=0.00824). A third
pathway,  melanoma,  achieved  a  significant  Bonferroni  p-
value (p=0.01634). The non-HK TM genes involved in the
focal adhesion and ECM-receptor interaction pathways are
presented in Table 2. Analysis of the 962 genes by GO led to
identification of many terms that achieved a highly significant
Bonferroni  p-value  within  the  categories  of  biologic
processes, molecular function, and cell component (Table 3).
Related biologic processes were merged manually, on the
basis of similarity between the processes and the fraction of
non-HK TM genes associated with these processes, as shown
in  Figure  2.  Genes  whose  expressions  had  been  reported
previously as changed due to glaucoma-relevant experimental
manipulations were considered next [8-11]. The distribution
of  these  genes  among  housekeeping  and  non-HK  TM
expressed genes is shown in Table 4, and the genes included
among the non-HK genes are presented in supplementary
Appendix 2. There was a trend toward preferential distribution
of the genes within the non-HK TM class of genes in all four
studies  tested,  although  the  difference  reached  statistical
significance in only two of the studies. Notably, the preference
is not observed in a study related to a non-TM ocular tissue
[21] that was tested for comparison (Table 4). Subsequently,
the 962 non-HK genes were submitted to BioProfiling to
identify miRNAs that may preferentially target non-HK TM
genes. No miRNA with a significant p-value was identified.
However,  enriched  miRNA  targets  were  identified  for
functionally clustered non-HK TM genes. Initially, the 962
non-HK TM genes were clustered into 26 groups by the Gene
Functional Classification option within DAVID (Appendix
3). Eleven of the groups contained more than ten non-HK TM
genes, and each of these groups was submitted separately to
BioProfiling; ten is the default minimum number of genes
accepted  by  this  software.  MicroRNAs  with  target  gene
enrichment (p≤0.05) were identified for four of the groups
(Table 5).
Finally, the TM expressed genes identified here were
compared to TM expressed genes reported earlier on the basis
of sequencing in two TM cDNA libraries and one SAGE
experiment [6,7,14]. As expected, most housekeeping genes
commonly used as reference genes in expression studies, and
expected to be expressed at high levels, were identified in all
four  studies  (Table  6A).  HPRT1  (hypoxanthine
phosphoribosyltransferase  1)  was  identified  only  in  the
microarray analysis presented here. Among the five known
Figure 1. Number of genes expressed in
human TM/number of times genes were
queried on chips. A: Number of genes
queried on chips of 1, 2, 3, or 4 of the
microarray studies of this meta-analysis
(% of all 21,813 genes queried at least
once).  B:  Among  genes  queried  2×,
number  of  genes  assessed  to  be
expressed  in  TM  1×  or  2×  (%  genes
queried 2×). C: Among genes queried
3×,  number  of  genes  assessed  to  be
expressed in TM 1, 2, or 3× (% genes
queried 3×). D: Among genes queried
4×,  number  of  genes  assessed  to  be
expressed in TM 1, 2,3, or 4× (% genes
queried 4×).
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243glaucoma-causing  genes–  MYOC  (myocilin),  CYP1B1
(cytochrome P450, family 1, subfamily B, polypeptide 1),
OPTN (optineurin), WDR36 (WDR36), and LTBP2 (latent
transforming growth factor beta binding protein 2)–all except
WDR36 were identified in three of the studies (Table 6B)
[22,23]. WDR36 was not identified in any of the studies.
FOXC1  (forkhead  box  C1)  and  PITX2  (paired-like
homeodomain  2),  genes  associated  with  glaucoma-related
Axenfeld-Rieger syndrome, were also identified in three of
the studies [24]. The study in which the glaucoma-related
genes were reported identified the lowest (386) number of TM
expressed genes and, probably, only those highly expressed
[6]. Only ten non-HK TM genes identified in the present
analysis were identified in all four studies, and these are most
likely to be highly expressed and consistently expressed non-
housekeeping genes of the human TM (Table 7). The ten genes
were ALDH1A1 (aldehyde dehydrogenase 1 family, member
A1), CDH11 (cadherin 11, type 2, OB-cadherin), CXCR7
(chemokine (C-X-C motif) receptor 7), CHI3L1 (chitinase 3-
like 1), FGF2 (fibroblast growth factor 2), GNG11 (guanine
nucleotide binding protein (G protein), gamma 11), IGFBP5
(insulin-like  growth  factor  binding  protein  5),  PTPRM
(protein  tyrosine  phosphatase,  receptor  type,  M),  RGS5
(regulator  of  G-protein  signaling  5),  and  TUSC3  (tumor
suppressor candidate 3). Among the interesting features of the
ten genes is that five (ALDH1A1,CDH11,CH13L1,FGF2, and
IGFBP5) were predicted by TargetScanHuman to be targeted
by microRNA-23a and −23b cluster microRNAs (mir-23ab,
mir-24, mir-27ab) and mir-204/211 (Table 7). Mir-24 and
mir-204/211 are microRNAs experimentally confirmed to be
expressed  in  the  TM  and  to  affect  expression  of  some
glaucoma-relevant  genes  [25,26].  Furthermore,  the
expression  of  mir-27,  which  was  predicted  to  target
CH13L1 and CXCR7, may be regulated by the glaucoma-
relevant  transcription  factor  PITX2  [27].  The  ten  genes
identified  in  all  the  studies  are  further  discussed  in  the
discussion section below.
DISCUSSION
The objective of this study was to identify non-housekeeping
genes definitively expressed in human TM cultured cells. We
aimed to minimize the consequences of individual variability
and experimental techniques. To this end, we performed meta-
analysis  on  four  available  microarray-based  global  gene
expression studies on human TM cultured cells. The data was
based on gene expression in 30 eyes of 15 individuals, 16–86
years of age. Cultured cells were used as surrogates for in vivo
conditions, due to obvious limitations in procuring native
tissue samples. Furthermore, as cultured cells are more likely
to be used by others because of the same limitations, this
analysis on cultured cells may be prove to be of greater use to
other  investigators.  Greater  than  90%  similarity  between
transcriptomes  of  TM  cultured  and  native  cells  has  been
reported,  albeit  the  differences  may  be  important  [10].
Classification of housekeeping genes is somewhat arbitrary;
we accepted all genes considered housekeeping in the most
recent microarray and/or RNA deep sequencing based studies
to be housekeeping genes. This low stringency was used to
minimize the possibility of inclusion of housekeeping genes
in our list of non-HK TM expressed genes. Ultimately, 962
TM  expressed  genes  are  proposed  to  be  part  of  the  non-
housekeeping  transcriptome  of  human  TM  cultured  cells.
Because stringent criteria were set for selection of these genes,
they are highly likely to be TM expressed genes. Nevertheless,
as  only  approximately  half  (4,417/8,416)  of  the  genes
considered here to be housekeeping genes met TM expression
criteria, it is expected that the 962 non-HK genes are not
inclusive of all non-HK genes expressed in the human TM.
Indeed, a few genes whose expressions in the TM are strongly
supported by experimental evidence were not among the 962
genes reported here, such as MEIS2 (Meis homeobox 2) [11].
True non-HK genes that are not included among the 962 genes
are likely biased toward those with lower levels of expression;
they are unlikely to be biased with respect to function. The
identified  genes,  therefore,  are  expected  to  reflect  the
morphological and functional properties of the human TM.
They identify molecular markers to be addressed in studies on
TM-related  biology,  including  the  TM-related  disease
glaucoma.
Analysis of the 962 genes by the DAVID bioinformatics
tool  identified  focal  adhesion  and  ECM-receptor  KEGG-
pathways  to  be  enriched  in  the  human  TM  at  a  highly
significant Bonferroni p value level. A recently published
gene expression profile of the normal human TM based on
SAGE data also included many genes related to extracellular
matrix, cell signaling, and cell structure/adhesion functions
[14]. The extracellular matrix of the TM is important with
respect to current understanding of TM function [28-31]. The
importance  of  the  ECM  with  respect  to  glaucoma  is
emphasized by the observation that two known glaucoma-
TABLE 2. BIOLOGIC PATHWAYS ENRICHED BY KEGG ANALYSIS OF NON-HOUSEKEEPING HUMAN TM EXPRESSED GENES (BONFERRONI P≤0.01).
Pathway Number of genes  Gene
Focal adhesion (Bonferroni
p=0.00275)
30 CAV2, CAV1, TLN2, PIP5K1C, VTN, MYL9, COL6A3, COL6A2, PDGFC, COL11A1, THBS2,
EGFR, COL4A2, COL4A1, PIK3CD, MET, ITGA2, HGF, FLNC, COL5A2, COL5A1, VEGFC,
LAMA4, CCND2, ITGA5, ITGA7, PDGFRA, PDGFRB, COL1A1, MYLK
ECM-receptor interaction
(Bonferroni p=0.00824)
17 COL4A2, COL4A1, HSPG2, ITGA2, VTN, COL5A2, COL5A1, LAMA4, SDC1, ITGA5, ITGA7,
COL6A3, COL6A2, SV2A, COL1A1, THBS2, COL11A1
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246causing genes are associated with this structure. The protein
product of MYOC, the first identified POAG gene, interacts
with  components  of  the  ECM  [32,33].  Furthermore,  the
protein  product  of  ADAMTS10  (ADAM  metallopeptidase
with  thrombospondin  type  1  motif,  10),  which  has  been
identified as causative of glaucoma in a canine model of the
disease,  is  involved  in  ECM  formation  [34,35].  Focal
adhesions are specialized structures formed at contact points
between cells and the ECM. In addition to structural links,
some  constituents  of  focal  points  are  signaling  molecules
whose  activities  culminate  in  reorganization  of  the  actin
cytoskeleton that, in turn, affects cell shape, cell motility, and
gene expression. Experimental evidence for involvement of
focal adhesion proteins such as paxillin in signaling pathways
in the human TM have been reported [36-38]. Among the 34
non-HK TM genes identified in the focal adhesion and ECM-
receptor pathways, 17 were common to both; the overlap is to
be expected, given the nature of the pathways (Table 2). Eight
of  the  17  common  genes  were  collagen-coding  genes.
Common  sequence  variants  near  CAV1  (caveolin  1)  and
CAV2, two of the genes only associated with focal adhesions,
were recently reported to be associated with primary open-
angle glaucoma [39]. The protein products of these genes
affect IOP levels and are involved in nitric oxide and TGF-β
(transforming  growth  factor  beta)  signaling  and  in  the
formation  of  caveolae  [39].  Caveolae  have  been  strongly
implicated in signal transduction. HGF (hepatocyte growth
factor),  another  of  the  focal  adhesion  associated  genes,
encodes hepatocyte growth factor. The concentration of this
protein  has  been  shown  to  be  significantly  higher  in  the
Figure  2.  Percent  of  non-HK  TM
expressed genes enriched in related gene
ontology biologic processes.
TABLE 4. DISTRIBUTION OF GENES WITH ALTERED EXPRESSION DUE TO EXPERIMENTAL MANIPULATIONS AMONG HOUSEKEEPING AND NON-HK TM
EXPRESSED GENES*.
Experimental
manipulation Reference
(No.) % HK TM
genes affected by
experimental
manipulation*
(No.) % non- HK TM
genes affected by
experimental
manipulation*
Statistical
significance
     % non-HK/% 
HK TM genes
affected by
experimental
manipulation
Treatment with
prostoglandin analogs
8 (25) 0.57 (8) 0.83 NS (p<0.50) 1.47
TGFβ¥ treatment 9 (35) 0.79 (49) 5.09 p<0.001 6.43
Glaucoma versus non-
glaucoma TM cells
10 (6) 0.14 (5) 0.51 NS (p~0.10) 3.82
PITX2 knockdown 11 (11) 0.25 (9) 0.94 p~0.001 3.76
Effect of aging on retina& 21 (8) 0.18 (1) 0.10 NS (p<0.75) 0.56
         *Affected genes are as reported in respective studies, and HK and non-HK genes refer to genes identified in present study; 
¥          transforming growth factor β; & represents a control treatment relating to a non-TM ocular tissue; NS=not significant.
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248aqueous  fluid  of  glaucomatous  eyes  [40].  Furthermore,
association  between  sequence  variations  in  HSP  and
glaucoma  has  recently  been  reported  in  the  Nepalese
population [41]. Analysis of the 962 genes with DAVID also
identified multiple enriched GO terms. ECM-related terms
were enriched in all three term categories—biologic process,
cellular  component,  and  cellular  function.  Among  the  14
cellular  component-enriched  terms,  seven  and  five,
respectively, were related to the ECM and plasma membrane.
The genes associated with these terms constituted 400 of the
962 non-HK TM expressed genes. The high representation of
ECM and plasma membrane-related terms is consistent with
enriched focal adhesion and ECM-receptor KEGG pathways,
and emphasizes that biologic processes related to these terms
are integral to the biologic roles of the TM.
The glaucoma-relevant parameters that were tested in the
genome-wide  TM  transcriptome  analyses  on  which  the
present study is based, were treatments with prostaglandin
analogs, transforming growth factor β, glaucoma status, and
PITX2  knockdown  [8-11].  It  was  observed  that  these
TABLE 6. TM EXPRESSED GENES IDENTIFIED IN MICROARRAY, CDNA LIBRARY, AND SAGE STUDIES.
  Study
 
Microarray studies
     
Gene All genes Non-HK genes cDNA library 1
β cDNA library 2
γ SAGE
δ
A.
Commonly
used
housekeeping
genes
GAPDH + - + + +
ACTB + - + + +
B2M + - + + +
HPRT1 + - - - -
B. Known
glaucoma
causing genes
CYP1B1 + + - + +
MYOC + + - + +
OPTN + - - + +
WDR36 - - - - -
LTBP2 + - - + +
FOXC1 + + - - +
PITX2 + + - + +
            α Present study; β reference [6]; γ reference [7]; δ reference [14]).
TABLE 7. TEN GENES IDENTIFIED IN ALL STUDIES AND MIRNAS PREDICTED TO TARGET THESE GENES.
Gene miRNAs*
ALDH1A1 mir-23ab
CDH11 mir-27ab, mir-144, mir-128, mir-26ab/1297, mir-214/761, mir-200bc/429, mir-101
CXCR7 mir-27ab, mir-142, mir-607, mir-524–5p, mir-520d-5p, mir-let7
CHI3L1 mir-24
FGF2 mir-23ab
GNG11 mir-587
IGFBP5 mir-24, mir-204/211, mir-130/301, mir-137, mir-139, mir-140, mir-193ab
PTPRM mir-130/301, mir-34abc, mir-205, mir-218, mir-148, mir-152
RGS5 mir-182
TUSC3 mir-30abc
           * Predicted by TargetScan.
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αtreatments  preferentially  affected  the  expression  of  genes
classified here as non-HK TM expressed genes (Table 4).
Although discussion of relevance of the genes with respect to
the treatments is beyond the scope of this presentation, their
enrichment in the non-HK class of genes suggests that the non-
HK  genes  identified  will  be  of  value  in  studies  aimed  at
achieving a better understanding of TM physiology.
Analysis  that  led  to  identification  of  miRNAs  with
enriched targets within one of the functionally related non-HK
TM group of genes (group 3) proved interesting. All the genes
placed  within  this  group  coded  collagen  proteins.  Much
evidence  on  the  role  of  collagens  in  TM  physiology  and
glaucoma pathogenesis is available in the literature [42-44].
Based on an association study, it was recently reported that
the collagen-coding gene COL5A1 (collagen, type V, alpha 1)
affects central corneal thickness, which is a glaucoma risk
factor [42]. Expressional elevation of COL8A2 (collagen, type
VIII, alpha 2) in TM cells in response to dexamethasone
treatment has also been observed, and it has been suggested
that this is part of the pathological process leading to steroid-
induced glaucoma [45,46]. Notably, rare COL8A2 mutations
have been found in some glaucoma patients [47]. Results of
experiments on cultured bovine TM cells have suggested that
increased expression of collagen type 4 causes resistance to
aqueous  outflow  [48].  Enriched  target  genes  for  all  three
members (miR-29a, b, and c) of the miR-29 family were found
within group 3 genes. It is already known that miR-29 family
members  regulate  expression  of  ECM  proteins,  including
collagen types 1, 4, and 5, in human TM cultured cells [49]
and in non-ocular tissues [50-55]. Experimental evidence for
their effect on collagen type 7, which is predicted here, has
not been reported. Effects of TGF-β and oxidative stress on
ECM synthesis in the human TM may be partially mediated
by miRNAs of this family [49]. Targets of six HSA-LET-7
family members were also significantly enriched in group 3
genes. To the best of our knowledge, experimental evidence
for effects of these miRNAs on collagen expression is not
available. HSA-LET-7F was also predicted to target ELF4
(E74-like factor 4), ETS1 (v-ets erythroblastosis virus E26
oncogene  homolog  1),  PLAGL2  (pleiomorphic  adenoma
gene-like 2), TEAD3 (TEA domain family member 3), and
HAND1 (heart and neural crest derivatives expressed 1) in
group 18 genes, although the p value (p=0.06) in this case did
not reach statistical significance (data not shown). Finally,
numerous  target  genes  for  miR-26  and  miR-34  family
members  were  identified  among  group14  non-HK  TM
expressed genes.
In addition to the genes discussed above, some non-HK
TM expressed genes identified in this study, as well as in
previous TM transcriptome studies, are of particular interest.
CH13L1  has  already  been  proposed  as  a  candidate  TM
marker, due to its high expression in the TM and restricted
expression in other tissues [10]. CH13L1 codes a carbohydrate
binding  lectin.  The  protein  directly  interacts  with  type  1
collagen, and this interaction may affect tissue remodeling
[56].  Involvement  of  CH13L1  in  the  pathogenesis  of
glaucoma has been considered [57-59]. ALDH1A1 codes an
aldehyde dehydrogenase that may be involved in minimizing
the deleterious effects of oxidative damage caused largely by
exposure of the anterior chamber to ultraviolet radiation [11,
60]. In addition, its expression in human TM cells is affected
by TGF-β treatment [9]. TGF-β signaling and oxidative stress
are both important components of glaucoma etiology [61].
FGF-2 encodes basic fibroblast growth factor 2 and has roles
in  angiogenesis.  Neovascular  glaucoma  is  a  rare  form  of
glaucoma [62]. It has been shown that the hormone ghrelin
inhibits FGF-2 mediated angiogenesis [63]. Notably, it has
been reported recently that ghrelin levels are significantly
lower in the aqueous humor of open-angle glaucoma patients,
than in control individuals [64]. RGS5 is of interest because
an alternatively spliced form of its mRNA was identified in
human ocular tissues, with highest expression of this form in
the TM [65]. In addition, an IGFBP-5 mRNA isoform with a
unique 3′-untranslated region only expressed in the TM has
been identified [66]. It would be of interest to determine if
mir-24 and mir-204/211, predicted to target IGFBP-5 mRNA,
may selectively affect specific isoforms. It has already been
shown that these miRNAs regulate multiple functions in TM
[25,26]. To the best of our knowledge, TM-specific properties
for CDH11, CXCR7, GNG11, PTPRM, and TUSC3 have not
been reported. CDH11 is an adhesion molecule, and CXCR7,
GNG11, and PTPRM are involved in cell signaling processes.
In  conclusion,  multiple  protein  coding  genes  and
miRNAs are introduced here as candidates for study for better
understanding  of  TM  physiology.  The  observation  that
experimental  data  have  already  implicated  many  of  the
identified genes and miRNAs in ocular functions supports the
premise that the remaining are also good candidates for further
study.
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253Appendix 1
Appendix  1.  Four  microarray/human  TM  gene
expression  studies:  housekeeping  and  non-housekeeping
genes expressed. To access the data, click or select the words
“Appendix 1.” This will initiate the download of a compressed
(pdf) archive that contains the file.
Appendix 2
Appendix 2. Non-HK TM genes with altered expression
due  to  glaucoma-relevant  exprimental  manipulations.  To
access the data, click or select the words “Appendix 2.” This
will initiate the download of a compressed (pdf) archive that
contains the file.
Appendix 3
Appendix  3.  Non-HK  human  TM  expressed  genes
grouped based on function. To access the data, click or select
the words “Appendix 3.” This will initiate the download of a
compressed (pdf) archive that contains the file.
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